Product Overview
Xeno Laboratories Tamox is tamoxifen citrate at 20 mg per tablet, the selective estrogen receptor modulator that most people meet first under the name Nolvadex. It has two jobs on this line and no others: it blocks the estrogen signal where that signal causes trouble, and it helps the pituitary resume the work that a suppressive course switched off. It adds no muscle and controls no aromatisation, and every figure below serves one of those two purposes.
Its mechanism is deliberately different from an inhibitor. Tamoxifen does not reduce how much estrogen is made; it occupies the receptor so the hormone cannot transmit its message in tissue such as the breast. That is why Arimidex and Aromasin are the tools for a high blood level and a SERM is the tool for a receptor problem. The tablet is also a prodrug: the liver turns it into metabolites, and one of those, N-desmethyltamoxifen, stays in the body for about a fortnight, while the parent compound clears in under a week. Effect and washout both run long after the last dose.
Those two roles explain how it is placed. On cycle it can be used in small amounts to protect breast tissue while a converting androgen or a nandrolone course runs. After that course it becomes the recovery drug, the option listed beside Clomiphene in every reference protocol, and a common partner to the injected step covered under HCG 5000 IU.
Dosage Protocol
The rows below are reference steps rather than a prescription, and the timing of the first tablet is as important as the amount. Tamoxifen is taken by mouth once a day.
| Beginner | A four week course at 20-40 mg daily is what ordinary practice uses |
| Intermediate | 40 mg a day for the first week, then the amount drops to 20 mg a day |
| Advanced | The same opening week followed by four to six weeks at 20 mg a day after deep suppression |
| Female | Out of scope for this page; in medicine the tablet is used against breast cancer |
| Administration | Oral once a day, with slow metabolism giving a long-acting effect |
| Duration | About four weeks, extended only where the hormone panel shows the axis still flat |
For the breast-protection role the amount is lower and the goal is different: a small daily dose is enough to keep the receptor occupied while the course runs, and the evidence gathered in men across a six-month period shows protection that scales with the amount. In recovery the logic reverses, because the aim is not to block a signal but to remove the feedback that keeps the pituitary quiet. The chapter of the plan decides which of the two is being asked for.
Suggested Protocols
The tablet appears in three arrangements. In each one it works with the rest of the plan rather than standing alone, and in each the hormone panel settles the question.
What to Expect
- The estrogen signal in breast tissue is blocked within one to two weeks, which is the change most users are watching for.
- Protection against breast symptoms is dose-dependent, according to the data gathered in men over six months.
- In recovery, endogenous testosterone rises across weeks two to four as the axis resumes its work.
- Clearance is slow because the active metabolite outlives the tablet, so the effect does not stop on the last day.
- Flushing and mood changes are common and usually respond to dose adjustment rather than to another product.
- Serious effects are uncommon but genuine, blood clots and visual disturbance among them; either one means stopping the course and getting medical attention.
Side Effects and Management
Post-Cycle Therapy
This tablet is one of the two SERMs that recovery protocols are built on, and it is measured by hormone results rather than by how the user feels in the second week.
The rest of the sequence is on its own pages: Clomiphene for the alternative route, HCG 5000 IU and HMG 75 IU for the injected step, and Proviron for the androgen side of the same plan.
